Notably, high levels of lymphocyte-activation gene-3 (LAG-3) and T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) in CAR T-cell infusion samples are associated with reduced ORR of CART19 cell therapy and an increased likelihood of early DLBCL relapse (59). The gene discussed is LAG3; the disease is diffuse large B-cell lymphoma.